Safety of human papillomavirus vaccines: A review

Drug Safety

Volumn 36, Issue 6, 2013, Pages 393-412

  Macartney, Kristine K ^a,b   Chiu, Clayton ^a,b   Georgousakis, Melina ^a   Brotherton, Julia M L ^c  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c VICTORIAN CYTOLOGY SERVICE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ANAPHYLAXIS; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FAINTNESS; FOLLOW UP; GUILLAIN BARRE SYNDROME; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; META ANALYSIS; NAUSEA; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SKIN REDNESS; SYSTEMATIC REVIEW; THYROIDITIS; VACCINATION; VENOUS THROMBOEMBOLISM;

EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; UTERINE CERVICAL NEOPLASMS; VACCINES, SYNTHETIC;

EID: 84878724531     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-013-0039-5     Document Type: Review

References (156)

1. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
2. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46:S20-6.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
4. Ferlay J, Shin H, Bray F, et al. GLOBOCAN 2008 v1. 2, cancer incidence and mortality worldwide: IARC CancerBase No. 10. Lyon: International Agency for Research on Cancer, 2010; 2012.
5. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24:S4-15.
6. Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sexual Reprod health. 2004;36:6-10.
7. Da Ros CT, da Silva Schmitt C. Global epidemiology of sexually transmitted diseases. Asian J Androl. 2008;10:110-4.
8. Harper DM. Currently approved prophylactic HPV vaccines. Expert Rev Vaccines. 2009;8:1663-79.
9. Chen J, Ni G, Liu XS. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: Immunological problems and future directions. Cell Immunol. 2011;269:5-9.
10. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301-14.
11. Rowhani-Rahbar A, Mao C, Hughes JP, et al. Longer term efficacy of a prophylactic monovalent human papillomavirus type 16 vaccine. Vaccine. 2009;27:5612-9.
12. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95:1459-66.
13. National Advisory Committee on Immunization (NACI). Update on human papillomavirus (HPV) vaccines. Can Commun Dis Rep. 2012;38:1-62.
14. Georgousakis M, Jayasinghe S, Brotherton J, et al. Population-wide vaccination against human papillomavirus in adolescent boys: Australia as a case study. Lancet Infect Dis. 2012;12:627-34.
15. Centre for Disease Control. Recommendations on the use of quadrivalent human papillomavirus vaccine in males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR. 2011;60:1705-8.
16. Australian Technical Advisory Group on Immunisation of the Australian Government Department of Health and Ageing. The Australian Immunisation Handbook. 10th ed. Canberra: Australian Government; 2013.
17. Giuliano AR, Palefsky JM, Goldstone S, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364:401-11.
18. Agorastos T, Chatzigeorgiou K, Brotherton JML, et al. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine. 2009;27:7270-81.
19. Brotherton J, Deeks SL, Campbell-Lloyd S, et al. Interim estimates of human papillomavirus vaccination coverage in the school-based program in Australia. Commun Dis Intell. 2008;32:457-61.
20. Buttery JP, Madin S, Crawford NW, et al. Mass psychogenic response to human papillomavirus vaccination. Med J Aust. 2008;189:261-2.
21. Konno R, Dobbelaere KO, Godeaux OO, et al. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women interim analysis of a phase ii, double-blind, randomized controlled trial at month 7. Int J Gynecol Cancer. 2009;19:905-11.
22. Neuzil KM, Canh do G, Thiem VD, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA. 2011;305:1424-31.
23. Zhu FC, Li CG, Pan HX, et al. Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years: a phase I trial. Chin J Cancer. 2011;30:559-64.
24. Kang S, Kim KH, Kim YT, et al. Safety and immunogenicity of a vaccine targeting human papillomavirus types 6, 11, 16 and 18: a randomized, placebo-controlled trial in 176 Korean subjects. Int J Gynecol Cancer. 2008;18:1013-9.
25. Kim YJ, Kim KT, Kim JH, et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years [Erratum appears in J Korean Med Sci. 2010 Dec;25(12):1831]. J Korean Med Sci. 2010;25:1197-204.
26. Kohl KS, Bonhoeffer J, Chen R, et al. The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf. 2003;12:335-40.
27. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics. 2006;118:2135-45.
28. Garland S, Hernandez-Avila M, Wheeler C, et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
29. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.
30. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J. 2007;26:201-9.
31. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial [see comment]. Lancet Oncol. 2005;6:271-8.
32. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine. Pediatr Infect Dis J. 2010;29:95-101.
33. Perez G, Lazcano-Ponce E, Hernandez-Avila M, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American women. Int J Cancer. 2008;122:1311-8.
34. Lazcano-Ponce E, Perez G, Cruz-Valdez A, et al. Impact of a quadrivalent HPV6/11/16/18 vaccine in Mexican women: public health implications for the region. Arch Med Res. 2009;40:514-24.
35. Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011;105:28-37.
36. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet. 2009;373(9679):1949-57.
37. Moreira ED Jr, Palefsky JM, Giuliano AR, et al. Safety and reactogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 viral-like-particle vaccine in older adolescents and young adults. Hum Vaccines. 2011;7:768-75.
38. Olsson SE, Villa LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25:4931-9.
39. Arguedas A, Soley C, Laoiza C, et al. Safety and immunogenicity of one done of MenACWY-CRM and investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine. 2010;28:3171-9.
40. Vesikari T, Van Damme P, Lindblad N, et al. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age. Pediatr Infect Dis J. 2010;29:314-8.
41. Wheeler CM, Bautista O, Tomassini JE, et al. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV) 6/11/16/18 L1 virus like particle (VLP) and hepatitis B (HBV) vaccines. Vaccine. 2008;26:686-96.
42. Descamps D, Hardt K, Spiessens B, et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccines. 2009;5:332.
43. Esposito S, Birlutiu V, Jarcuska P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study. Pediatr Infect Dis J. 2011;30:e49-55.
44. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-55.
45. Khatun S, Akram Hussain SM, Chowdhury S, et al. Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh. Jpn J Clin Oncol. 2012;42:36-41.
46. Kim SC, Song YS, Kim YT, et al. Human papillomavirus 16/18 AS04-adjuvanted cervical cancer vaccine: immunogenicity and safety in 15-25 years old healthy Korean women. J Gynecol Oncol. 2011;22:67-75.
47. Medina DM, Valencia A, de Velasquez A, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolesc Health. 2010;46:414-21.
48. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161-70.
49. Pedersen C, Petaja T, Strauss G, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40(6):564-71.
50. Petaja T, Keranen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009;44:33-40.
51. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine. 2009;27:581-7.
52. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757-65.
53. Petaja T, Pedersen C, Poder A, et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer. 2011;129:2147-57.
54. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial [Erratum appears in Lancet Oncol. 2012 Jan;13(1):e1]. Lancet Oncol. 2012;13:89-99.
55. Schwarz TF, Huang LM, Medina DM, et al. Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10-14 years. J Adolesc Health. 2012;50:187-94.
56. Schwarz TF, Spaczynski M, Schneider A, et al. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15-55 years. Hum Vaccines. 2011;7:958-65.
57. Romanowski B, Schwarz TF, Ferguson LM, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccines. 2011;7:1374-86.
58. Garcia-Sicilia J, Schwarz TF, Carmona A, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine to girls and young women. J Adolesc Health. 2010;46:142-51.
59. Pedersen C, Breindahl M, Aggarwal N, et al. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. J Adolesc Health. 2012;50:38-46.
60. Schmeink CE, Bekkers RLM, Josefsson A, et al. Co-administration of human papillomavirus-16/18 AS04-adjuvanted vaccine with hepatitis B vaccine: randomized study in healthy girls. Vaccine. 2011;29:9276-83.
61. Wheeler CM, Harvey BM, Pichichero ME, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Pediatr Infect Dis J. 2011;30:e225-34.
62. Verstraeten T, Descamps D, David MP, et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine. 2008;26:6630-8.
63. Rambout L, Hopkins L, Hutton B, et al. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ Can Med Assoc J. 2007;177:469-79.
64. Koutsky L, Ault K, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-51.
65. Lu B, Kumar A, Castellsague X, et al. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis. 2011;11:1-16.
66. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199:926-35.
67. Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009;199:936-44.
68. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107:18-27.
69. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix (TM) and Gardasil (R) human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccines. 2009;5:705-19.
70. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccines. 2011;7:1343-58.
71. Smith-McCune K. Quadrivalent HPV vaccine administered to women who became pregnant during trials did not appear to adversely affect pregnancy outcome; however, use during pregnancy is not recommended. Evid Based Med. 2010;15:80-1.
72. Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol. 2009;114:1170-8.
73. Forinash AB, Yancey AM, Pitlick JM, et al. Safety of the HPV bivalent and quadrivalent vaccines during pregnancy. Ann Pharmacother. 2011;45:258-62.
74. Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009;114:1179-88.
75. TM]. Coverage the period from first approval (June 1, 2006) through May 31, 2011. http://www.merckpregnacyregisteries.com (Accessed January, 2013).
76. Wacholder S, Chen BE, Wilcox A, et al. Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials. BMJ. 2010;340:c712.
77. GalaxoSmithKline Pregnancy Registries. Cervarix™ Pregnancy Registry [online]. http://pregnancyregistry.gsk.com/cervarix.html (Accessed January, 2013).
78. Pasternak B, Svanström H, Mølgaard-Nielsen D, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A (H1N1) vaccine during pregnancy. JAMA. 2012;308:165-74.
79. Department of Health. Chapter 18a Human papillomaviurs (HPV). In: Salisbury D, Ramsay M, Noakes K, editors. The 'Green Book': immunisation against infectious disease. London: The Stationary Office; 2012.
80. Markowitz LE, Dunne EF, Saraiya M, et al. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1-24.
81. Jacobson RM, Adegbenro A, Pankratz VS, et al. Adverse events and vaccination-the lack of power and predictability of infrequent events in pre-licensure study. Vaccine. 2001;19:2428-33.
82. ®. Vaccine. 2010;28:4719-30.
83. Medicines and Healthcare products Regulatory Agency (MHRA). YellowCard [online]. 2012. http://yellowcard.mhra.gov.uk/the-yellow-card-scheme/ (Accessed August, 2012).
84. Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), agencies of the U.S. Department of Health and Human Services. Vaccine Adverse Events Reporting System [online]. 2012. http://vaers.hhs.gov/index (Accessed August, 2012).
85. Iskander JK, Miller ER, Chen RT. Vaccine adverse event reporting system (VAERS). Pediatr Ann. 2004;33:599.
86. Public Health Agency of Canada. Adverse events following immunization reporting form [online]. 2012. http://www.phac-aspc.gc.ca/im/aefi-essi-form-eng. php (Accessed 28th June).
87. Hawcutt DB, Mainie P, Riordan A, et al. Reported paediatric adverse drug reactions in the UK 2000-2009. Br J Clin Pharmacol. 2012;73:437-46.
88. Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Drug Inf J. 2008;42:409-19.
89. Huang WT, Huang WI, Huang YW, et al. The reporting completeness of a passive safety surveillance system for pandemic (H1N1) 2009 vaccines: a capture-recapture analysis. Vaccine. 2012;30:2168-72.
90. Centre for Disease Control. Withdrawal of rotavirus vaccine recommendation. MMWR Wkly Rep. 1999;48:1007.
91. Collet JP, MacDonald N, Cashman N, et al. Monitoring signals for vaccine safety: the assessment of individual adverse event reports by an expert advisory committee. Bull World Health Organ. 2000;78:178-85.
92. Kliewer EV, Demers AA, Brisson M, et al. The Manitoba human papillomavirus vaccine surveillance and evaluation system. Health Rep. 2010;21:37-42.
93. Australian Government Department of Health and Ageing TGA. Human papillomavirus vaccine (Gardasil) advice from the therapeutic drug administration [online]. 2010. http://www.tga.gov.au/safety/alerts-medicine- gardasil-070624.htm (Accessed 27th June).
94. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA J Am Med Assoc. 2009;302:750-7.
95. van 't Klooster TM, Kemmeren JM, Vermeer-de Bondt PE, et al. Human papillomavirus vaccination catch-up campaign in 2009 for girls born in 1993 to 1996 in the Netherlands: results of the post-marketing safety surveillance. 2011.
96. The Medicines and Healthcare products Regulatory Agency (MHRA). Cervarix (HPV vaccine): update on UK safety covering the first two years of the HPV immunisation programme. 2010.
97. Brotherton JML, Gold MS, Kemp AS, et al. Anaphylaxis following quadrivalent human papillomavirus vaccination. Can Med Assoc J. 2008;179:525-33.
98. Kang LW, Crawford N, Tang MLK, et al. Hypersensitivity reactions to human papillomavirus vaccine in Australian schoolgirls: retrospective cohort study. Br Med J. 2008;337:a2642.
99. Labadie J. Postlicensure safety evaluation of human papilloma virus vaccines. Int J Risk Saf Med. 2011;23:103-12.
100. Advisory Committee on Immunization Practices. Summary Report. Antlanta: Department of Health and Human Services, Centre for Disease Control and Prevention; 2011.
101. Centre for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) Summary Report. Atlanta: Centre for Disease Control and Prevention; 2011.
102. NHS Choices. HPV vaccine in the clear [online]. 2009. http://www.nhs.uk/news/2009/09September/Pages/Cervical-cancer-vaccine-QA.aspx (Accessed August, 2012).
103. Larson HJ, Brocard P, Garnett G. The India HPV-vaccine suspension. Lancet. 2010;376:572-3.
104. Pandhi D, Sonthalia S. Human papilloma virus vaccines: current scenario. Indian J Sex Transm Dis. 2011;32:75.
105. Institute of Medicine of the National A. Adverse events: evidence and causality. Washington, D.C.: The National Academies Press; 2011.
106. Richards S, Chalkiadis G, Lakshman R, et al. Complex regional pain syndrome following immunisation. Arch Dis Childhood. 2012;97:913-5.
107. Ojaimi S, Buttery JP, Korman TM. Quadrivalent human papillomavirus recombinant vaccine associated lipoatrophy. Vaccine. 2009;27:4876-8.
108. Siegrist CA, Lewis EM, Eskola J, et al. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Pediatr Infect Dis J. 2007;26:979-84.
109. Sutton I, Lahoria R, Tan I, et al. CNS demyelination and quadrivalent HPV vaccination. Multiple Scler. 2009;15:116-9.
110. Cooper Robbins SC, Bernard D, McCaffery K, et al. "I just signed": Factors influencing decision-making for school-based HPV vaccination of adolescent girls. Health Psychol. 2010;29:618-25.
111. LaRussa PS, Edwards KM, Dekker CL, et al. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network. Pediatrics. 2011;127:S65-73.
112. Wood NJ. The role of the Immunisation Adverse Events Clinic at The Children's Hospital at Westmead. N S W Public Health Bull. 2010;21:234-6.
113. Singh Y, Shah A, Singh M, et al. Human papilloma virus vaccination in Nepal: an initial experience in Nepal. Asian Pac J Cancer Prev. 2010;11:615-7.
114. Gasparini R, Bonanni P, Levi M, et al. Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study. Hum Vaccines. 2011;7(Suppl):136-46.
115. Naleway AL, Gold R, Drew L, et al. Reported adverse events in young women following quadrivalent human papillomavirus vaccination. J Women's Health. 2012;21:425-32.
116. Erlewyn-Lajeunesse M, Hunt LP, Heath PT, et al. Anaphylaxis as an adverse event following immunisation in the UK and Ireland. Arch Dis Childhood. 2012;97:487-90.
117. Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf. 2012;21:1350-8.
118. O'Leary ST, Glanz JM, McClure DL, et al. The risk of immune thrombocytopenic purpura after vaccination in children and adolescents. Pediatrics. 2012;129:248-55.
119. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271:193-203.
120. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29:8279-84.
121. Yih WK, Kulldorff M, Fireman BH, et al. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink Project. Pediatrics. 2011;127:S54-64.
122. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012;166:1140-8.
123. Tricotel A. Human papillomavirus vaccine and autoimmune disorders: a cohort study of 5.8 millions of adolescents and young women. Two years follow-up results. Fundam Clin Pharmacol. 2011;25:1.
124. Siegrist CA. Autoimmune diseases after adolescent or adult immunization: What should we expect? Can Med Assoc J. 2007;177:1352-4.
125. Callréus T, Svanström H, Nielsen NM, et al. Human papillomavirus immunisation of adolescent girls and anticipated reporting of immune-mediated adverse events. Vaccine. 2009;27:2954-8.
126. Van 't Klooster TM, Kemmeren JM, Van Der Maas NAT, et al. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV) 16/18 vaccine in the Netherlands. Vaccine. 2011;29:4601-7.
127. Crawford NW, Clotheir HJ, Elia S, et al. Syncope and seizures following human papillomavirus vaccination: a retrospective case series. Med J Aust. 2011;194:16-8.
128. Centre for Disease Control. General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2011;60:1-60.
129. Centre for Disease Control. Syncope after vaccination - United states, January 2005-July 2007. MMWR. 2008;57:457-60.
130. Centre for Disease Control. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR. 2010;59:626-9.
131. Souayah N, Michas-Martin P, Nasar A, et al. Guillain-Barré syndrome after Gardasil vaccination: data from vaccine adverse event reporting system 2006-2009. Vaccine. 2011;29:886-9.
132. World Health Organisation. Global Advisory Committee on Vaccine Safety, 17-18 December 2008. Wkly Epidemiol Rec (WER). 2009;5:37-40.
133. European Centre for Disease Prevention and Control (ECDC). Introduction of HPV vaccines in European Union countries - an update. Stolkholm: ECDC; 2012.
134. World Health Organisation. Global Advisory Committee on Vaccine Safety, 12-13 June 2007. Wkly Epidemiol Rec (WER). 2007:245-60.
135. Markowitz LE, Hariri S, Unger ER, et al. Post-licensure monitoring of HPV vaccine in the United States. Vaccine. 2010;28:4731-7.
136. Gold MS, McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sexual Health. 2010;7:320-4.
137. Mahajan D, Campbell-Lloyd S, Cook J, et al. NSW annual report describing adverse events following immunisation, 2010. N S W Public Health Bull. 2011;22:196-208.
138. Mahajan D, Reid S, Cook J, et al. NSW annual report describing adverse events following immunisation, 2011. N S W Public Health Bull. 2013;23:187-200.
139. Studdiford J, Lamb K, Norvath K, et al. Development of unilateral cervical and supraclavicular lymphadenopathy after human papillomavirus vaccination. Pharmocotherapy. 2008;28:1194-7.
140. Debeer P, De Munter P, Bruyninckx F, et al. Brachial plexus neuritis following HPV vaccination. Vaccine. 2008;26:4417-9.
141. Marsee DK, Williams JM, Velazquez EF. Aluminum granuloma after administration of the quadrivalent human papillomavirus vaccine. Report of a case. Am J Dermatopathol. 2008;30:622-4.
142. Das A, Chang D, Biankin A, et al. Pancreatitis following human papillomavirus vaccination. Med J Aust. 2008;189:178.
143. Schaffer V, Wimmer S, Rotaru I, et al. HPV vaccine: a cornerstone of female health a possible cause of ADEM? J Neurol. 2008;255:1818-20.
144. Wildemann B, Jarius S, Hartmann M, et al. Acute disseminated encephalomyelitis following vaccination against human papillomavirus. Neurology. 2009;72:2132-3.
145. DiMario FJ Jr, Hajjar M, Ciesielski T. A 16 year old girl with bilateral visual loss and left hemiparesis following an immunisation against human papillomavirus. J Child Neurol. 2010;25:321-7.
146. Wehbe E. A catastrophic failure. Am J Med. 2011;124:e7-9.
147. Bomprezzi R. Acute disseminated encephalomyelitis following vaccination against human papillomavirus. Neurology. 2010;72:2132-3.
148. Chang J, Campagnolo D, Vollmer TL, et al. Demyelinating disease and polyvalent human papilloma virus vaccination. J Neurol Neurosurg Psychiatry. 2011;82:1296-8.
149. Blitshteyn S. Postural tachycardia syndrome after vaccination with Gardasil. Eur J Neurol. 2010;17:e52.
150. Khalifa Y, Monahan P, Acharya N. Ampiginous choroiditis following quadrivalent human papilloma virus vaccine. Br J Ophthalmol. 2010;94:137-9.
151. McCarthy JE, Filiano J. Opsoclonus myoclonus after human papilloma virus vaccine in a pediatric patient. Parkinson Relat Disord. 2009;15:792-4.
152. Tuccori M, Pisani C, Bachini L, et al. Telogen effluvium following bivalent human papillomavirus vaccine administration: a report of two cases. Dermatology. 2012;224:212-4.
153. Rossi M. Bilateral papilledema following human papillomavirus vaccination. J Med Cases. 2011;2:222-4.
154. Pugnet G, Ysebaert L, Bagheri H, et al. Immune thrombocytopenic purpura following human papillomavirus vaccination. Vaccine. 2009;27:3690.
155. Soldevilla H, Briones S, Navarra S. Systemic lupus erythematosus following HPV immunization or infection? Lupus. 2012;21:158-61.
156. van't Klooster T, Kemmeren J, van der Maas N, et al. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine. 2011;29:4601-7.